Recently, the same research group identified a dihydroquinolone pyrazoline (DHQP)-based inhibitor which also disrupted the RAD51-BRCA2 interaction, inhibited HDR activity and showed synergy with olaparib in pancreatic cancer to trigger synthetic lethality (172). Here, BRCA2 is linked to familial pancreatic carcinoma.